Loading
PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Acute lymphoblastic leukaemia and 2 more. This dossier gathers the 1 product (0 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarisation and migration by regulating the spatial accumulation of PIP3 and by regulating the organisation of F-actin formation and integrin-based adhesion at the leading edge. Location: Cytoplasm; Cell membrane (UniProt). Locus 7q22.3 (HGNC).
| Modality | Phase 2 |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 2 | Completed | A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naïve, Advanced Urothelial Carcinoma | - | ||
| 1 | Historic | A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors | - | ||
| 1 | Recruiting | Safety of Targeting PI3Kgamma Signaling With Azacitidine, Venetoclax and Eganelisib in Acute Myeloid Leukemia: A Phase 1 Study (GAVEL) | - | ||
| 1 | Recruiting | A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher Risk Myelodysplastic Syndrome and Eganelisib in Combination With Azacitidine in PI3K-Gamma-Positive Patients With Previously Untreated Higher Risk Myelodysplastic Syndrome | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"PIK3CG" OR ABSTRACT:"PIK3CG" OR TITLE:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma" OR ABSTRACT:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma" OR TITLE:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform" OR ABSTRACT:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PIK3CG, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/pik3cg.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/pik3cg.json. Licence CC BY-NC 4.0.